GenMark Dx Plans Respiratory Viral, CYP450 Panels as Q2 Revenues Rise 162 Percent | GenomeWeb

By Justin Petrone

GenMark Diagnostics this week reported revenue growth of 162 percent for its first quarter since going public in the US.

The company, which was based in London and known as Osmetech before going public in the US at the end of May, also announced that it is seeking a new CEO. Jon Faiz Kayyem, who previously served in that role, is now chief scientific officer. Christopher Gleeson, chairman of the firm, will serve as CEO on an interim basis.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.

In Nucleic Acids Research this week: personal genome approach to RNA-seq read alignment, hematopoietic Systems Biology Repository, and more.

A man is using DNA evidence to argue that he is the rightful heir to the baronetcy of Stichill, the Guardian reports.

As part of an effort to get a diverse group of people to donate their DNA for research, some blood donors in the San Diego area will get their genomes sequenced, according to KPBS.

The comment period on the Department of Health and Human Services' proposal to alter the Common Rule has been extended.

Sponsored by
Agilent Technologies

This online seminar will discuss a metagenomic assay to identify viruses and other pathogenic microorganisms in human tumor samples, with the aim of gaining a more comprehensive understanding of the role of the microbiome in cancer development and treatment.